Survivors of thyroid cancer have a higher risk of developing age-associated diseases compared with patients who never had cancer, particularly if they were younger than 40 years at the time of diagnosis.
No clear effect in most cases of a second radioactive iodine (RAI) treatment in patients with differentiated thyroid cancer with biochemical or structural regional incomplete response to initial thyroidectomy and RAI therapy.
No regional or distant metastases developed during active surveillance in low-risk patients.
Revised ATA guidelines have led to an increased interest in risk-adopted management strategies for differentiated thyroid cancer.
Irregular users of thyroxine were less likely to develop thyroid cancer compared to regular users.
Stroke risk with I-131 therapy for thyroid cancer was examined via 2 cohorts using 1:1 propensity score matching.
Thyroid cancer screening in asymptomatic adults was given a D recommendation because of the negative effects of screening outweighing any benefits.
Multiple studies at ENDO 2017 highlighted the dangers linked to both environmental toxin and common household chemical exposure.
Patients with government subsidized or self-pay insurance were less likely to undergo thyroidectomy for thyroid cancer.
Increases in papillary thyroid cancer were most common between 1974 and 2013.
Endocrinology Advisor Articles
- Soluble Klotho Levels Predictive of Kidney Failure in Type 2 Diabetes
- HbA1c Levels Predictive of Liraglutide Treatment Response in T2D
- Comorbid and Pharmacologic Factors Increase Risk for Gastrointestinal Disorders in Diabetes
- ADA Updates Guidelines for Cardiovascular Risk Management in Diabetes
- Clinicians May Be Overtreating Older Patients With Diabetes
- USPSTF Issues Recommendation for Vitamin D, Calcium Supplementation for Fracture Prevention
- Obesity Risk in Infants Born to Women With Diabetes
- Insulin-Treated Diabetes Reduces Dysglycemia-Related Mortality in Sepsis
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Oxyntomodulin Augments Glucose Homeostasis